Gene expression profiles associated with chronic allograft nephropathy
AssigneeThe Scripps Research Institute
InventorsDaniel R. Salomon, Sunil M. Kurian, Steven R. Head
Life of this patent
Estimating the term…
Abstract
By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with chronic allograft nephropathy and/or interstitial fibrosis and tubular atrophy CAN/IFTA and subtypes thereof. These genes sets are useful for diagnosis, prognosis, monitoring and/or subtyping of CAN/IFTA.
Claims20
A method of prognosing, diagnosing or monitoring CAN/IFTA (chronic allograft nephropathy, interstitial fibrosis and tubular atrophy, or chronic allograft nephropathy and interstitial fibrosis and tubular atrophy), comprising
- (a) determining expression levels in a subject of at least 5 genes selected from the genes in Table A, B, C, D, E, F, G, H, I and/or J;
- and
- (b) prognosing, diagnosing or monitoring CAN/IFTA in a subject from the expression levels.
An array, comprising a support or supports bearing a plurality of nucleic acid probes complementary to a plurality of mRNAs fewer than 5000 in number, wherein the plurality of mRNAs includes mRNAs expressed by at least five genes selected from Table A, B, C, D.
A method of subtyping a CAN/IFTA, comprising (a) determining expression levels in a subject of at least 5 genes selected from the genes in Tables A, B, C, D;
- E, F, G, H, I and/or J;
- and (b) determining a subtype of CAN/IFTA from the expression levels.
Dependencies are inferred from the claim text.